Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

• Main Authors: Andrew Blauvelt (Author), Richard G. Langley (Author), Patrick J. Branigan (Author), Xuejun Liu (Author), Yanqing Chen (Author), Samuel DePrimo (Author), Keying Ma (Author), Brittney Scott (Author), Kim Campbell (Author), Ernesto J. Muñoz-Elías (Author), Kim A. Papp (Author)
• Format: Book
• Published: Elsevier, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23-driven IL-17-producing T cell and other IL-23 receptor-positive IL-17-producing cell responses. Selective blockade of IL-23p19 with guselkumab was superior to blockade of TNF-α with adalimumab (ADA)...